FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010073405> ?p ?o ?g. }

• W3010073405 endingPage "1396" @default.
• W3010073405 startingPage "1388" @default.
• W3010073405 abstract "In animal models cis-palmitoleic acid (9-hexadecenoic acid; 16:1n-7c), a lipokine, improves insulin sensitivity, inflammation, and lipoprotein profiles; in humans trans-palmitoleic acid (16:1n-7t) has been associated with lower incidence of type 2 diabetes. The response to dose-escalation of supplements containing cis- and trans-palmitoleic acid has not been evaluated.We examined dose-escalation effects of oral supplementation with seabuckthorn oil and seabuckthorn oil augmented in 16:1n-7t on serum phospholipid fatty acids (PLFAs).Thirteen participants (7 women and 6 men; age 48 ± 16 y, BMI 30.4 ± 3.7 kg/m2) participated in a randomized, double-blind, crossover, dose-escalation trial of unmodified seabuckthorn oils relatively high in 16:1n-7c (380, 760, and 1520 mg 16:1n-7c/d) and seabuckthorn oils augmented in 16:1n-7t (120, 240, and 480 mg 16:1n-7t/d). Each of the 3 escalation doses was provided for 3 wk, with a 4-wk washout period between the 2 supplements. At the end of each dose period, fasting blood samples were used to determine the primary outcomes (serum concentrations of the PLFAs 16:1n-7t and 16:1n-7c) and the secondary outcomes (glucose homeostasis, serum lipids, and clinical measures). Trends across doses were evaluated using linear regression.Compared with baseline, supplementation with seabuckthorn oil augmented in 16:1n-7t increased phospholipid 16:1n-7t by 26.6% at the highest dose (P = 0.0343). Supplementation with unmodified seabuckthorn oil resulted in a positive trend across the dose-escalations (P-trend = 0.0199). No significant effects of either supplement were identified on blood glucose, insulin, lipids, or other clinical measures, although this dosing study was not powered to detect such effects. No carryover or adverse effects were observed.Supplementation with seabuckthorn oil augmented in 16:1n-7t and unmodified seabuckthorn oil moderately increased concentrations of their corresponding PLFAs in metabolically healthy adults, supporting the use of supplementation with these fatty acids to test potential clinical effects in humans.This trial was registered at clinicaltrials.gov as NCT02311790." @default.
• W3010073405 created "2020-03-13" @default.
• W3010073405 creator A5008352140 @default.
• W3010073405 creator A5018985930 @default.
• W3010073405 creator A5033014448 @default.
• W3010073405 creator A5064987258 @default.
• W3010073405 creator A5076862251 @default.
• W3010073405 creator A5087239434 @default.
• W3010073405 date "2020-06-01" @default.
• W3010073405 modified "2023-10-12" @default.
• W3010073405 title "Supplementation with Seabuckthorn Oil Augmented in 16:1n–7tIncreases SerumTrans-Palmitoleic Acid in Metabolically Healthy Adults: A Randomized Crossover Dose-Escalation Study" @default.
• W3010073405 cites W1849396925 @default.
• W3010073405 cites W1963915610 @default.
• W3010073405 cites W1993540550 @default.
• W3010073405 cites W2017602185 @default.
• W3010073405 cites W2037407152 @default.
• W3010073405 cites W2043788271 @default.
• W3010073405 cites W2053307994 @default.
• W3010073405 cites W2093534308 @default.
• W3010073405 cites W2116404316 @default.
• W3010073405 cites W2135024461 @default.
• W3010073405 cites W2146237755 @default.
• W3010073405 cites W2146598568 @default.
• W3010073405 cites W2151042915 @default.
• W3010073405 cites W2151604950 @default.
• W3010073405 cites W2153738368 @default.
• W3010073405 cites W2157685039 @default.
• W3010073405 cites W2160234571 @default.
• W3010073405 cites W2168526937 @default.
• W3010073405 cites W2295848014 @default.
• W3010073405 cites W2571799777 @default.
• W3010073405 cites W2607031541 @default.
• W3010073405 cites W2787798593 @default.
• W3010073405 cites W2802021370 @default.
• W3010073405 cites W2896906720 @default.
• W3010073405 cites W2932155525 @default.
• W3010073405 cites W2946226678 @default.
• W3010073405 cites W2946513226 @default.
• W3010073405 doi "https://doi.org/10.1093/jn/nxaa060" @default.
• W3010073405 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7269729" @default.
• W3010073405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32140719" @default.
• W3010073405 hasPublicationYear "2020" @default.
• W3010073405 type Work @default.
• W3010073405 sameAs 3010073405 @default.
• W3010073405 citedByCount "9" @default.
• W3010073405 countsByYear W30100734052021 @default.
• W3010073405 countsByYear W30100734052022 @default.
• W3010073405 countsByYear W30100734052023 @default.
• W3010073405 crossrefType "journal-article" @default.
• W3010073405 hasAuthorship W3010073405A5008352140 @default.
• W3010073405 hasAuthorship W3010073405A5018985930 @default.
• W3010073405 hasAuthorship W3010073405A5033014448 @default.
• W3010073405 hasAuthorship W3010073405A5064987258 @default.
• W3010073405 hasAuthorship W3010073405A5076862251 @default.
• W3010073405 hasAuthorship W3010073405A5087239434 @default.
• W3010073405 hasBestOaLocation W30100734051 @default.
• W3010073405 hasConcept C126322002 @default.
• W3010073405 hasConcept C140793950 @default.
• W3010073405 hasConcept C142724271 @default.
• W3010073405 hasConcept C185592680 @default.
• W3010073405 hasConcept C204787440 @default.
• W3010073405 hasConcept C27081682 @default.
• W3010073405 hasConcept C2778084480 @default.
• W3010073405 hasConcept C2779641957 @default.
• W3010073405 hasConcept C2780809830 @default.
• W3010073405 hasConcept C543025807 @default.
• W3010073405 hasConcept C55493867 @default.
• W3010073405 hasConcept C71924100 @default.
• W3010073405 hasConcept C86803240 @default.
• W3010073405 hasConcept C87813604 @default.
• W3010073405 hasConceptScore W3010073405C126322002 @default.
• W3010073405 hasConceptScore W3010073405C140793950 @default.
• W3010073405 hasConceptScore W3010073405C142724271 @default.
• W3010073405 hasConceptScore W3010073405C185592680 @default.
• W3010073405 hasConceptScore W3010073405C204787440 @default.
• W3010073405 hasConceptScore W3010073405C27081682 @default.
• W3010073405 hasConceptScore W3010073405C2778084480 @default.
• W3010073405 hasConceptScore W3010073405C2779641957 @default.
• W3010073405 hasConceptScore W3010073405C2780809830 @default.
• W3010073405 hasConceptScore W3010073405C543025807 @default.
• W3010073405 hasConceptScore W3010073405C55493867 @default.
• W3010073405 hasConceptScore W3010073405C71924100 @default.
• W3010073405 hasConceptScore W3010073405C86803240 @default.
• W3010073405 hasConceptScore W3010073405C87813604 @default.
• W3010073405 hasFunder F4320310609 @default.
• W3010073405 hasFunder F4320332161 @default.
• W3010073405 hasFunder F4320332605 @default.
• W3010073405 hasIssue "6" @default.
• W3010073405 hasLocation W30100734051 @default.
• W3010073405 hasLocation W30100734052 @default.
• W3010073405 hasLocation W30100734053 @default.
• W3010073405 hasOpenAccess W3010073405 @default.
• W3010073405 hasPrimaryLocation W30100734051 @default.
• W3010073405 hasRelatedWork W1004635292 @default.
• W3010073405 hasRelatedWork W2147961043 @default.
• W3010073405 hasRelatedWork W2358114756 @default.
• W3010073405 hasRelatedWork W2389294044 @default.
• W3010073405 hasRelatedWork W2389481126 @default.

• next